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AbstrACt 
Introduction Poor adherence to photoprotection for 
people with xeroderma pigmentosum (XP) can be 
life-threatening. A randomised controlled trial (RCT) is 
being conducted to test the efficacy of a personalised 
adherence intervention (XPAND) to reduce the level of 
ultraviolet radiation (UVR) reaching the face, by improving 
photoprotection activities in adults with XP.
Methods and analysis A two-armed parallel groups RCT, 
where we randomised 24 patients with suboptimal adherence 
to either an intervention group who received XPAND in 2018 
or a delayed intervention group who will receive XPAND in 
2019. XPAND involves seven sessions, one-to-one with a 
facilitator, using behaviour change techniques and specially 
designed materials to target barriers to photoprotection. 
Following baseline assessment in April 2018 (t0) and 
intervention, the primary outcome will be measured across 
21 consecutive days in June and July 2018 (t1). The primary 
outcome is the average daily UVR dose to the face (D-to-F), 
calculated by combining objective UVR exposure at the 
wrist (measured by a dosimeter) with face photoprotection 
activities recorded on a daily UVR protection diary. Secondary 
outcomes include average daily UVR D-to-F across 21 days 
in August (t2); psychosocial process variables measured by 
daily questions (t0, t1, t2) and self-report questionnaires (t0, t1, 
t2, December 2018 (t3)). Intervention cost-utility is assessed 
by service use and personal cost questionnaires (t0, t3). The 
delayed intervention control arm participants will complete 
three further assessments in April 2019 (t4) and June–July 
2019 (t5), and December 2019 (t6) with dosimetry and UVR 
protection diary completed for 21 days at t4 and t5. A process 
evaluation will be conducted using mixed methods.
Ethics and dissemination Ethical approval has been 
received from West London & GTAC REC 17/LO/2110. 
Results will be disseminated in peer-reviewed journals 
and at conferences. This study tests a novel intervention, 
which, if successful, will be integrated into routine care.
trial registration number NCT03445052; Pre-results.
IntroduCtIon
Xeroderma pigmentosum (XP) is a very rare 
genetic condition, where the body is unable 
to repair ultraviolet radiation (UVR)-in-
duced damage to DNA caused by daylight.1 
Any UVR exposure dramatically increases the 
chances of developing skin and eye cancers 
(eg, rates of non-melanoma skin cancer 
increase 10 000-fold).2 Photoprotection is 
recommended for the healthy population and 
those taking medications which may cause 
photosensitivity. However, it is essential for 
people with XP. There is currently no cure 
for this disease and the only way to minimise 
and delay the cancers is meticulous and abso-
lute photoprotection every day. Photopro-
tection involves a complex set of behaviours 
(ie, application of broad-spectrum SPF50 
sunscreen, wearing long sleeves and long 
trousers or skirts, wide brimmed hat, glasses, 
face scarf or buff and avoiding UVR expo-
sure by staying indoors). The best way of 
protecting the face is by wearing a face visor 
(a legionnaire style hat with a UVR-protec-
tive transparent film at the front). Analysis of 
strengths and limitations of this study
 ► To the best of our knowledge, this is the first ran-
domised controlled trial to evaluate an adherence 
intervention designed to improve photoprotection 
in people diagnosed with xeroderma pigmentosum.
 ► We have a primary outcome which is clinically 
relevant.
 ► We control for seasonal differences in environmental 
ultraviolet radiation exposure by comparing between 
groups across the same weeks.
 ► We include a process evaluation to understand par-
ticipant views of XPAND which will be important 
when integrating the intervention into current clin-
ical care.
 ► Recruitment and retention of participants may be 
difficult in this extremely rare disease.
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self-reported photoprotection used by 21 adults with XP 
in the UK revealed that over half were using ‘very poor’ 
or no photoprotection for at least 20% of all outdoor 
time.3 This poor photoprotection has life-threatening 
consequences.
In common with other rare conditions,4 little is known 
about the psychological and behavioural patient-re-
lated factors that have the potential to improve health 
outcomes in patients with XP. In recognition of this 
deficit, the National Institute of Health Research (NIHR) 
agreed to fund a novel programme of research to inves-
tigate the psychosocial factors associated with non-ad-
herence to photoprotection in XP (RP-PG-1212–20009: 
Developing a psychological intervention to improve 
ultraviolet protection and clinical outcomes in XP). The 
aims of the grant were twofold: to identify the drivers of 
non-adherence using complex mixed-methods research 
(qualitative interviews; cross-sectional survey; n-of-1; 
diary-dosimeter measures)5 (known as ‘Phase One’) and 
to use this knowledge to design and test an intervention 
to improve adherence (‘Phase Two’). We identified 17 
modifiable psychosocial drivers of non-adherence to 
photoprotection activities from Phase One. These drivers 
or barriers to optimal photoprotection relate to factors 
influencing the motivation to protect (eg, doubts about 
perceived necessity of photoprotection) and volitional 
factors limiting the enactment of photoprotection activi-
ties, even if motivation is high (eg, lack of habit). Findings 
from the mixed-methods research studies are published 
separately.3 6 7
We aimed to systematically develop an adherence 
intervention to improve photoprotection in XP. There is 
growing support for interventions focused on changing 
patient beliefs about their illness and treatment, trans-
lating into improvements in adherence across a range 
of chronic conditions.8–10 This suggests that addressing 
unhelpful illness and treatment beliefs may be an 
important treatment target for photoprotection in XP. 
Furthermore, a recent systematic review found evidence 
in support of the effectiveness of psychosocial interven-
tions to improve adherence to photoprotective activities 
among non-XP individuals at elevated risk for melanoma 
(due to personal or family history11).
We designed a personalised intervention titled, 
‘XPAND: Enhancing XP Photoprotection Activities – New 
Directions’, using intervention mapping.12 Intervention 
mapping starts by breaking the desired behaviour and 
determinants of behaviour into constituent parts, which 
are mapped to theory and translated to intervention 
components. Relevant theories to guide the interven-
tion design included the Necessity and Concerns Frame-
work,13 Common Sense Model of Illness Regulation14 
and the Theoretical Domains Framework (not a theory 
itself but it combines the components of social cognition 
models used to explain behaviour).15 A full description 
of the development of the intervention, the process of 
personalisation and the final intervention product will be 
reported separately.
This paper describes the protocol for a randomised 
controlled trial (RCT) to test the efficacy of XPAND to 
lower the dose of UVR reaching the face, by improving 
adherence to photoprotection. This can be achieved by 
minimising overall UVR exposure (ie, time spent outside) 
and by increasing level of photoprotection worn or 
applied when outside. The primary objective is to reduce 
the average daily UVR dose to the face (D-to-F) across 21 
days in June to July (2018), immediately after the delivery 
of the main intervention. Secondary objectives are: to 
maintain reductions in average daily UVR D-to-F across 
21 days in August 2018 (after a booster session has been 
delivered to the intervention group); to increase and then 
maintain daily ratings of mood, self-efficacy, goal priority, 
automaticity and photoprotection activities across the 
two 21-day periods. Tertiary objectives are to explore 
intervention-related changes from baseline. A qualitative 
process evaluation will investigate the acceptability, feasi-
bility and change mechanisms from the perspective of the 
participant. We will conduct a cost-utility analysis, which 
will indicate whether implementation into clinical care is 
economically viable.
MEthods And AnAlysIs
Participants and recruitment
People diagnosed with XP and registered at the National 
XP Service at Guy’s and St Thomas’ NHS Foundation 
Trust will be recruited into the trial. Eligible patients will 
be sent an invitation letter, followed by a telephone call 
from the research nurse, and those interested will be sent 
the study information leaflet. Following a second call, if 
they wish to participate, they will give written consent at 
a home visit. Patients will be reminded that participation 
in the study is voluntary and that they may withdraw at 
any time. No payment will be given for participation. 
Screening and recruitment will take  place between 
February and March 2018.
Inclusion criteria
1. A confirmed diagnosis of XP (reduced DNA repair ac-
tivity in DNA fibroblast assay, in a clinical context com-
patible with a diagnosis of XP and with confirmation 
by finding pathogenic mutations in an XP gene on 
gene sequencing)
2. Aged ≥16 years
3. Suboptimal adherence to photoprotection when out-
doors, as identified by the XP clinical team from data 
held in medical notes, or by the research team from 
data collected during the Phase One studies:
a. Score <20 on our Adherence to Photoprotection 
scale (where a total score of 25 indicates optimal 
photoprotection)16
b. Using photoprotective clothing combinations for 
the face that have been assessed by the clinical team 
as anything other than ‘excellent’ or ‘very good’ an-
ytime outdoors,3 recorded on the daily UVR protec-
tion diary
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c. Having a ‘resistant’ or ‘integrated’ mode of adjust-
ment to photoprotection, as identified in the quali-
tative analysis7
Exclusion criteria
1. Diagnosed with cognitive impairment (XP or non-XP 
related) due to potential impact on the efficacy of the 
intervention and on the participants’ experiences of 
taking part.
2. Non-fluent in English (to enable in-depth discussion 
with the intervention facilitators)
3. Diagnosed with current clinical depression or anx-
iety, as detailed in medical notes, or confirmed after 
completion of Hospital Anxiety and Depression Scale 
(HADS)17 at the baseline home visit
study design and flowchart
The XPAND trial is a phase II two-armed parallel group 
RCT, with a delayed intervention control arm. Partici-
pants are randomised to either the intervention group 
who receive the XPAND intervention in addition to 
routine care between April and June 2018 or the control 
group who receive routine care in 2018 and then XPAND 
between April and June 2019. The delayed interven-
tion control group is included to maximise information 
collection about the intervention due to the extremely 
rare nature of XP. For example, achievable sample sizes 
limit the ability to test between-group differences for the 
psychosocial outcomes with acceptable power and the 
delayed intervention group allows for intervention-re-
lated changes from baseline testing, which is less robust 
but still useful.
Patient flow through the study is described in figure 1. 
The baseline assessment takes place in April 2018 (t0). 
Post-randomisation assessments take place after comple-
tion of the intervention in June to July 2018 (t1), after a 
booster session in August 2018 (t2) and after a long-term 
follow-up in December 2018 (t3). All participants use a 
wrist-worn UVR dosimeter continuously from t0 to t2 and 
complete daily UVR protection diaries for 21 consecutive 
days at each assessment time point. At each assessment, 
participants additionally complete patient-reported 
outcomes. The t3 follow-up does not involve dosimetry 
Figure 1 Progression of participants through the study.
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or daily UVR protection diary. In addition, the delayed 
intervention control arm only completes three further 
assessments in April 2019 (t4) and June–July 2019 (t5), 
and December 2019 (t6) with dosimetry and daily UVR 
protection diary completed for 21 days at t4 and t5.
A nested qualitative study examining acceptability and 
mechanisms of change will be conducted in the inter-
vention group after the August assessment period is 
completed.
The study is funded by the NIHR Programme Grants 
for Applied Research scheme (RP-PG-1212–20009) and 
received ethical approval.
randomisation
Participants will be randomised, in blocks using an equal 
allocation ratio, to receive XPAND immediately (2018) or 
to the delayed group stratified by burning type to attempt 
to balance those with an extreme (ie, scoring between 
1 and 3 on the sunburn severity score18) versus normal 
burning response. Participants who are in the same family 
will be randomised as a cluster to the same group to avoid 
contamination. Since all participants will be recruited at 
the point of randomisation, the trial statistician (SN) will 
generate a random allocation sequence for all partici-
pants together, using a computer programme with fixed 
block sizes of 4, to ensure equal allocation to both groups. 
To protect the integrity of the randomisation, partici-
pants in the immediate intervention group will be asked 
not to reveal their allocation to those outside their imme-
diate family. Group allocation will be concealed from the 
XP clinical team who are not part of the research team 
(excluding the PI) to avoid inadvertent changes to the 
standard care of these participants during the trial (eg, 
greater/lesser discussion of adherence during routine 
clinical appointments). Moreover, as both the control and 
intervention groups might receive opportunistic encour-
agement from the clinical team to protect, this would not 
adversely affect the trial outcome.
Primary outcome
The primary outcome is the average daily UVR D-to-F 
(standard erythemal dose (SED)), across 21 consecutive 
days between June and July 2018 (t1), following comple-
tion of six out of seven intervention sessions by the inter-
vention group. UVR D-to-F is estimated by combining 
data from a UVR dosimeter worn on the wrist (SunSaver 
3, Bispebjerg Hospital, Copenhagen, Denmark)19 and the 
patient’s photoprotective activities, self-reported using 
the daily UVR protection diary. The dosimeter was set to 
measure UVR levels every 5 s and record the average every 
5 min, which has been validated as providing reliable 
measurements of total UVR exposure over the course of a 
day.20 The combination of the daily UVR protection diary 
and dosimeter to estimate UVR D-to-F has been used in 
our earlier research with this population (Phase One) 
and demonstrated to function sufficiently well to be the 
primary outcome in this trial. The paper-based daily UVR 
protection diary allows participants to record periods of 
time spent outside (in 15 min intervals) and the timing of 
any specific photoprotection activities while outside (ie, 
wearing a face visor, hat, hoodie worn-up, glasses, scarf or 
face buff or applying sunscreen and lip block) by drawing 
a line on a grid (see online supplementary file 1). To 
avoid errors in recording, each participant will receive 
training on how to complete the diary. UVR D-to-F will be 
calculated using the dose recorded at the wrist weighted 
by the level of protection provided by the combination 
facial photoprotection behaviours used.5
secondary outcomes
The following outcomes relate to between-group compar-
isons in 2018 and are recorded on the daily UVR protec-
tion diary. UVR-related outcomes also use data from the 
dosimeter.
a. Average daily UVR D-to-F across 21 consecutive days in 
August 2018 (t2). This is to investigate the stability of 
any improvement identified in the primary outcome 
period (June to July 2018), as it will be 4–6 weeks after 
the main intervention and follows session 7 (the boost-
er session).
b. Average daily total UVR exposure during each of the 
21 day periods (t1, t2) and the average daily time out-
side across all daylight hours and restricted to 11:00–
15:00, when UVR levels are at their highest. These data 
will be gathered from the dosimeter and the UVR pro-
tection diary.
c. Average daily proportion of time outside across day-
light hours and between 11:00 and 15:00 with ‘very 
good’ or ‘excellent’ face photoprotection during each 
of the 21 day periods (t1, t2). The categorisations relate 
to the Daily Photoprotection Scale (DPS)3 developed 
for the Phase One n-of-1 study in consultation with the 
UK XP clinical team. Facial photoprotection activities 
(excluding sunscreen) are ranked according to their 
relative level of photoprotection. The following com-
binations are classed as ‘very good photoprotection’: 
hat, glasses and scarf/buff; hat, glasses, scarf/buff and 
hoodie. ‘Excellent photoprotection’ is wearing a face 
visor, which completely covers the face.
d. Average daily proportion of time outside across day-
light hours with sunscreen protection, defined as when 
sunscreen was applied within the previous 3 hours, 
during each of the 21 day periods (t1, t2).
e. Average daily number of times sunscreen is applied ir-
respective of time outside during each of the 21 day 
periods (t1, t2).
f. Average daily measures of mood, automaticity of photo-
protection activities, prioritisation of photoprotection 
compared with other priorities and level of self-effi-
cacy to manage barriers during the two follow-up pe-
riods (t1, t2) will be assessed. The single items have 
been adapted from ecological momentary assessment 
questions used in our n-of-1 study3 (eg, How much 
do you agree that UVR protection of your face today 
was something you did automatically without thinking 
(0=strongly disagree to 10=strongly agree)) and are 
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included on the UVR protection diary (see online sup-
plementary file 1).
tertiary outcomes
The following outcomes are assessed once, at the start of 
each 21 day period (t0, t1, t2, t3). Health-related quality 
of life (HRQoL), psychological well-being, automaticity 
of photoprotection activities, self-efficacy in the context 
of barriers and self-rated photoprotection adherence will 
be measured using self-report questionnaires. Data will be 
combined across t1 and t2 to assess proximal impact of 
the intervention and t3 will be used to assess stability of 
impact.
See table 1 for the schedule of self-reported measures.
a.  HRQoL will be assessed using the EQ-5D-5L21
b. Emotional well-being will be measured by the Short-
form Warwick Edinburgh Mental Well-Being Scale 
(SWEMWBS)22
c. Automaticity of photoprotection activities will be 
assessed using the 4-item Self-Report Behavioural 
Automaticity Index (SRBAI),23 adapted to photopro-
tection. It is a validated subscale of the Self-Report 
Habit Index24 which focuses on the automaticity of be-
haviour. It asks respondents to rate the extent to which 
they agree with each statement on a seven-point Likert-
type scale (eg, UVR photoprotection is something I do 
without thinking (1=strongly disagree to 7=strongly 
agree)). The average of responses gives a score be-
tween 1 and 7, with higher scores indicating greater 
automaticity.
d.  Self-efficacy to photoprotect will be measured us-
ing a 21-item scale (Photoprotection Self-Efficacy 
Questionnaire (PhotoSEQ)) developed for this study, as 
no validated questionnaire specific to photoprotection 
activities in the presence of barriers, as recommended 
by Bandura,25 was identified (see online supplemen-
tary file 2). Three items ask the respondent to rate 
their level of confidence that they can carry out a type 
of photoprotection activity (eg, shifting timing and/
or duration of outdoor activity, photoprotection us-
ing clothing, correctly apply sunscreen) on a 10-point 
scale (0=Not at all – 10=very confident); two items ask 
separately about confidence to wear photoprotective 
clothing and apply sunscreen in the presence of nine 
different barriers in the following 4 weeks (eg, How 
confident are you that you can photoprotect even if/
when: unexpected things get in the way). Two sub-
scales are calculated, an average self-efficacy score for 
sunscreen and similarly for photoprotective clothing 
and shifting time/duration of activity. Higher scores 
indicate greater self-efficacy.
e. A secondary brief measure of photoprotection activi-
ties was developed to assess photoprotection to indi-
cate whether improvements in photoprotection are 
maintained, when participants will not be completing 
the daily UVR protection diary at t3 (see online supple-
mentary file 3.). To allow comparison with the diary, 
it will be completed at all follow-up points. The Brief 
Photoprotection Adherence Questionnaire (BPAQ) 
has five items and assesses duration of time outdoors, 
and photoprotection used when outdoors during the 
previous 7 days. Three items assess different ways of 
protecting outdoors: how often respondents wore pro-
tective clothing (eg, When you went outside, how often 
did you protect your face against UVR using protective 
clothing? (0=never to 10=all the time)); the number of 
days sunscreen was applied in the morning (0–7 days); 
Table 1 Summary of self-reported measures schedule
Intervention and control groups 2018 Delayed intervention group only 2019
Baseline 
(t0)
(April)
Follow-up 
(t1)
(June–July)
Follow-
up(t2)
(August)
Follow-up 
(t3)
(December)
Follow-up 
(t4) (April)
Follow-up 
(t5)
(June– July)
Follow-up 
(t6)
(December)
UVR Protection Diary ✓ ✓ ✓ ✓ ✓
EuroQol five dimensions 
questionnaire (EQ-5D)
✓ ✓ ✓ ✓ ✓ ✓ ✓
Short-form Warwick-Edinburgh 
Mental Well-Being Scale 
(SWEMWBS)
✓ ✓ ✓ ✓ ✓ ✓ ✓
Self-Report Behavioural Automaticity 
Index’ (SRBAI)
✓ ✓ ✓ ✓ ✓ ✓ ✓
Photoprotection Self-efficacy 
Questionnaire (PhotoSEQ)
✓ ✓ ✓ ✓ ✓ ✓ ✓
Brief Photoprotection Adherence 
Questionnaire (BPAQ)
✓ ✓ ✓ ✓ ✓ ✓ ✓
Service Use Questionnaire (SUQ) ✓ ✓ ✓ ✓
Feedback questionnaire (intervention 
group only)
✓ ✓
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and how often sunscreen was reapplied when outdoors 
for longer periods (0=not at all to 10=always). Two 
items ask respondents to estimate average duration 
of time outdoors each day (Never, <30 min, 31 min–1 
hour, 2 hours, upwards in hourly intervals to >8 hours) 
and average duration of time outdoors each day be-
tween 11:00 and 15:00 when environmental UVR levels 
are highest. Each item will be analysed separately.
Further exploratory analyses will examine change from 
baseline incorporating the delayed intervention group 
allowing for higher power to assess intervention-related 
changes. These will be undertaken unblinded to group 
allocation after main efficacy analyses are complete.
the XPAnd intervention
XPAND is composed of a combination of one-to-one 
sessions and materials purposely designed to target 
barriers to photoprotection. It was designed to be deliv-
ered by a healthcare professional (HCP) without specialist 
psychological training (eg, clinical nurse specialist). In 
the trial context, facilitators will be two psychologists and 
a research nurse.
One-to-one sessions
Facilitators will deliver 7x one-to-one sessions to each 
participant. Further information on the structure of 
the intervention is available in figure 2. Each session 
will include a combination of personalised and generic 
content. The intervention content and techniques were 
systematically developed and selected using intervention 
mapping.12 Core strategies delivered to all participants 
will include those to increase self-efficacy, self-regulatory 
skills and the automaticity of photoprotection. In addi-
tion, personalised modules will be delivered, as needed, 
selected initially based on data collected in Phase One 
studies and a profiling questionnaire, and iteratively as 
additional barriers emerge during the sessions. The facili-
tators will use a communication style consistent with moti-
vational interviewing.26 They will be guided by a manual, 
including theory-based behaviour change methods 
mapped to recognised taxonomies,12 27 and specific tech-
niques from other therapeutic approaches (eg, Accep-
tance and Commitment Therapy).28
Intervention materials
Patient-facing materials have been developed and will 
be provided to participants in session one and used 
throughout the intervention to facilitate discussion, 
provide real-life examples and reinforce the concepts and 
skills discussed during the sessions. These are summarised 
in figure 2.
sample size calculations
The target sample size for the study is a total of 24 
patients (ie, 12 per group), which was based on the ability 
to detect an average daily UVR D-to-F difference of 0.10 
SED between the groups during the June to July 2018 
assessment period. This difference was considered clin-
ically meaningful and potentially achievable due to the 
personalised nature of the intervention. From our Phase 
One study of UVR exposure, the average daily UVR D-to-F 
for people diagnosed with XP was 0.27 SED (SD=0.14), 
with a within-person correlation of rICC=0.31. Thus, the 
anticipated difference relates to an effect size of d=0.73, 
Figure 2 Structure of the XPAND intervention.  
 o
n
 5 August 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-028577 on 17 July 2019. Downloaded from 
7Walburn J, et al. BMJ Open 2019;9:e028577. doi:10.1136/bmjopen-2018-028577
Open access
or just over a one-third reduction in average daily UVR 
D-to-F. Adjusting for the design effect due to the depen-
dence of assessments within individuals, a sample size 
of 20 patients with 21 daily observations has 80% power 
to detect a reduction of 0.10 SED in average daily UVR 
D-to-F at the 5% significance level. Accounting for attri-
tion of 20%, based on our previous research, the target 
sample size was set at 24.
statistical analyses
The main efficacy analyses will be conducted by the trial 
statistician (SN) following a prespecified analysis plan 
and blind to group allocation. The analysis will follow 
the intention to treat principle with individuals analysed 
within the groups to which they were randomised irre-
spective of whether they received or persisted with the 
intervention.
The treatment effect on the primary outcome of daily 
UVR D-to-F over 21 days between June and July 2018 and 
secondary outcome of daily UVR D-to-F over 21 days in 
August will be estimated simultaneously using a linear 
mixed model. Given the skewed distribution of UVR 
D-to-F, a logarithmic transformation will be applied and 
robust SE will be estimated. A random intercept will 
account for the repeated assessments of UVR D-to-F within 
individuals across all 42 days, with an autoregressive error 
structure to account for correlation between assessments 
across successive days. In addition to the dummy-coded 
group variable, other covariates in the model include a 
dummy-coded variable for the assessment period (June–
July vs August), an assessment period by group interac-
tion, the patients baseline average daily UVR, an indictor 
variable for the patients propensity to burn and the back-
ground level of UVR recorded by the observatory closest 
to the patients’ house on the day. Data will be summarised 
as the empirical Bayes estimate of the average daily UVR 
D-to-F in SEDs for each assessment period for each group.
This approach allows for missing daily data within each 
individual under the assumption that data are missing at 
random. We will run sensitivity analyses to explore the 
influence of missing data on the effect estimates, so as 
to allow for a consideration of the likely plausible range 
for the treatment effect under a number of missing not 
at random assumptions. For average daily assessments, 
where these are not available for the full 21 days, this will 
involve imputing missing values under a range of conser-
vative assumptions using the average daily values of the 
group to which the individual is assigned using a pattern 
mixture model approach (eg, average daily level +0.0 SED 
to 0.5 SED).
Treatment effects for average daily levels of mood, 
self-efficacy, goal priority, automaticity and time outside 
will be analysed for both assessment periods simulta-
neously using mixed-effects as described above. Treat-
ment effects for adherence, self-efficacy, automaticity, 
HRQoL and psychological well-being taken at the start 
of the June and August assessment periods will also be 
estimated using linear mixed models but will specify an 
unconstrained error structure. It is not anticipated that 
transformation will be required to account for skew in 
any of these outcomes; however, robust SE will be esti-
mated. Covariates included in the analysis will be the 
same as above except that baseline levels of the outcomes 
will be included in place of baseline average daily UVR 
D-to-F. Scale scores will be calculated using proration to 
account for missing items within the scale where there is 
at most one-third of items missing. For example, where 
scale includes six items, at least four items must have 
been completed. Otherwise, the scale score will be set to 
missing for that individual.
Further exploratory analysis using dynamic regression 
models will evaluate changes in both level and variability 
in daily UVR exposure over time between March and 
September, accounting for treatment using a regression 
discontinuity approach. This is possible as the dosim-
eter will be worn for the entire period. However, due to 
patient burden and since the UVR protection diary is only 
completed for 3-week intervals, it will also be necessary to 
calculate UVR D-to-F using average daily photoprotection 
during the pre and post diary intervals. This differs from 
the main analysis where UVR D-to-F is calculated directly 
based on photoprotection activities recorded on the diary.
Process evaluation
A mixed-methods process evaluation, using qualitative 
interviews and self-report measures, will explore the 
acceptability of the intervention, changes in photopro-
tection activities and psychosocial mechanisms of change. 
A brief intervention feedback questionnaire, completed 
immediately after session 6, will be used to record more 
proximal perceptions of the main content of interven-
tion. Responses to this questionnaire and the profiling 
questionnaire (see figure 2) will be used to guide prompts 
during these interviews and give insight into psychosocial 
mechanisms of change.
The feedback questionnaire is adapted from one used 
to assess a fat reduction intervention.29 It has five items 
assessing overall perceptions of the programme and 
its components, the impact on photoprotection activi-
ties and whether psychosocial variables have changed 
as a result of the intervention. The questions assess the 
extent to which respondents agree with statements about 
the intervention (eg, ‘Overall the programme was inter-
esting’ (1=strongly disagree to 5=completely agree)) (see 
online supplementary file 4).
In-depth qualitative interviews will be conducted by 
a research nurse and health psychologist who were 
involved in the design and delivery of the intervention. 
They will not interview participants to whom they deliv-
ered the intervention. Interviews will be based on a topic 
guide and will explore participants’ views of and experi-
ences with XPAND, including more practical delivery-re-
lated aspects, such as the optimal number of sessions, 
preference for telephone or skype sessions and the value 
of any further booster sessions. All interviews will be 
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audio-recorded, transcribed and coded using thematic 
analysis30 31 in NVivo V.10.
Fidelity assurance
A fidelity assessment will be undertaken to examine the 
extent to which facilitators delivered the key components 
of the intervention, specified in the intervention manual, 
during the face-to-face sessions. Independent researchers 
will apply a fidelity checklist to audio recordings of all 
session 1 s and session 6 s, as well as and a random selec-
tion of subsequent sessions.
Evaluation of the cost-utility of XPAnd
A decision model will be used to assess the cost-effective-
ness of the intervention. Decision models allow outcomes 
and costs associated with alternative care process to be 
investigated via simulations. Model structures simplify the 
care process such that specific aspects can be focused on. 
Advantages of these models are that they can be adapted 
to reflect the outcomes and costs that occur in a variety 
of settings (and therefore aid generalisability); they allow 
evidence to be generated in a time and cost-efficient way; 
and they enable interventions to be evaluated that may 
be precluded using trial methods. The structure of the 
model to be used here will be developed by the health 
economists in collaboration with the clinical researchers, 
and will consist of health states that patients may be in 
over time. Transition between the states will be informed 
by literature on the progression of the condition, expert 
opinion and data collected through the trial. The impact 
of the intervention on these transitions will be deter-
mined through the clinical trial. A health service perspec-
tive will be used followed by a societal perspective, which 
will incorporate broader costs.
Service use will be measured via completion of a Client 
Service Receipt Inventory (CSRI).32 This retrospectively 
assesses use of primary and secondary healthcare services 
(including surgical interventions), social care, tests/inves-
tigations and aids and adaptations (see online supple-
mentary file 5). The cost of these inputs will be calculated 
by combining the service use data with appropriate unit 
cost information. Other impacts of XP include addi-
tional financial costs for the patient (eg, sunscreen); and 
time lost from work/education by patients (eg, to attend 
appointments, receive treatment, manage symptoms). 
Costs of these effects will be calculated using average 
wage rates and information on returns to education. 
Costs will be combined with quality-adjusted life years 
(QALYs) derived from the EQ-5D-5L. The estimated cost 
of the intervention will be based on staff time required to 
deliver it, plus additional training and materials.
trial management
An independent Trial Steering Committee (TSC) 
attended by the research team, two independent 
researchers and one patient and public involvement 
(PPI) panel member will meet every 3 months to provide 
oversight of the trial. Trial data are collected after each 
measurement period by a member of the research team 
not delivering the intervention to that individual. Data 
are managed and entered by the research team, not the 
statisticians analysing the data. Adverse events are defined 
as events that occur during participation in the trial. All 
will be recorded (death; life threatening; hospitalisation; 
self-harm; attendance at A&E; distress (intervention 
group)) and reported to the TSC, who will make a judge-
ment on the link to the trial and recommend modifica-
tions or discontinuing trial as appropriate.
Patient and public involvement
PPI has been integral to every step in the development of 
this protocol. The PPI panel advised on the study design, 
particularly related to participant burden of completion 
of the daily UVR protection diary, which informed the 
decision to limit the follow-up of the delayed intervention 
control group to a single period of 21 days (June–July 
2019, t5). In addition, the panel reviewed all the XPAND 
intervention participant-facing materials which helped 
ensure they were appropriate and acceptable. The PPI 
panel were not involved in the recruitment process. A 
summary of research findings will be sent to all partici-
pants and published papers will be made available.
dIsCussIon
To the best of our knowledge, this is the first RCT to test a 
behaviour change intervention to improve adherence to 
photoprotection in adults with XP; an ambitious under-
taking in a rare disease. It uses a robust methodology, 
both in the systematic development of the intervention 
and in the use of a clinically relevant novel measurement 
approach to estimate dose of UVR reaching the face. The 
inclusion of a process evaluation will provide insight into 
the workings of the intervention and the mechanism 
underlying our trial outcomes, as well as information 
about the acceptability of XPAND, a key consideration 
for the implementation of the intervention into routine 
clinical care. We will also have estimates of the cost-effec-
tiveness of the intervention. Furthermore, over and above 
the obvious clinical advantages of decreasing the risk of 
morbidity and mortality associated with skin cancer for 
the UK XP population, if the intervention is efficacious, 
it will be generalisable to international populations of 
adults with XP, significant for other conditions requiring 
photoprotection (eg, Systemic Lupus Erythematosus) 
and relevant for healthy populations.
EthICs And dIssEMInAtIon
This research has been approved. The findings will be 
published in peer-reviewed journals and presented at 
national and international scientific conferences.
trial status
Recruitment completed. Patient involvement in the study 
will conclude in December 2019.
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